These findings support previous data by our group and others demonstrating that the functional signaling activation of the PI3K/AKT/mTOR pathway in breast cancers, including in metastatic lesions, cannot be fully explained by the underlying genomic profile of the tumor48,49. Here, MTOR is linked to breast cancer.